Prioritization of therapy uncertainties in Dystrophic Epidermolysis Bullosa: where should research direct to? an example of priority setting partnership in very rare disorders
Authors:
- Paula Davila-SeijoPDPaula Davila-Seijo
- Angela Hernández-MartínAHAngela Hernández-Martín
- Evanina Morcillo-MakowEMEvanina Morcillo-Makow
- Raúl de LucasRLRaúl de Lucas
- Esther DomínguezEDEsther Domínguez
- Natividad RomeroNRNatividad Romero
- Eva MonrósEMEva Monrós
- Marta FeitoMFMarta Feito
- Luis CarreteroLCLuis Carretero
- Bea AraneguiBABea Aranegui
- Ignacio García-DovalIGIgnacio García-Doval
Open Access
- 1 January 2013
- journal article
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 8 (1) , 61
Abstract
Dystrophic Epidermolysis Bullosa (DEB) is a rare genodermatosis (7 cases per million) that causes blisters and erosions with minor trauma in skin and mucosa, and other systemic complications. A recently updated systematic review showed that the research evidence about DEB therapies is poor. As new trials in DEB are difficult and expensive, it is important to prioritizise research that patients and clinicians consider more relevant.Keywords
This publication has 27 references indexed in Scilit:
- A Novel Zebrafish Xenotransplantation Model for Study of Glioma Stem Cell InvasionPLOS ONE, 2013
- Systematic reviews and uncertainties about the effects of treatments2010
- Future research into the treatment of vitiligo: where should our priorities lie? Results of the vitiligo priority setting partnershipBritish Journal of Dermatology, 2010
- Genitourinary Tract Involvement in Epidermolysis BullosaDermatologic Clinics, 2010
- Nutrition for Children with Epidermolysis BullosaDermatologic Clinics, 2010
- Type VII Collagen: The Anchoring Fibril Protein at Fault in Dystrophic Epidermolysis BullosaDermatologic Clinics, 2010
- A systematic review of randomized controlled trials of treatments for inherited forms of epidermolysis bullosaClinical and Experimental Dermatology, 2008
- Patient and public involvement in clinical trialsBMJ, 2008
- Relation between agendas of the research community and the research consumerThe Lancet, 2000
- The National epidermolysis Bullosa Registry.Journal of Investigative Dermatology, 1994